felmetatug vedotin

{
  "id": "MLC-T-ONC-013551",
  "term": "felmetatug vedotin",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a protease-cleavable peptide linker, with potential antineoplastic activity. Upon administration of anti-B7-H4 ADC SGN-B7H4V, the anti-B7-H4 monoclonal antibody moiety targets and binds to B7-H4 expressed on tumor cells. Upon binding, internalization and linker cleavage, MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and apoptosis specifically in B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and tumor-associated macrophages (TAMs). It negatively regulates T-cell immune responses. In addition, SGN-B7H4V may also kill B7-H4-expressing tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).",
  "synonyms": [
    "ADC SGN-B7H4V",
    "anti-B7-H4 ADC SGN-B7H4V",
    "anti-B7-H4 antibody-drug conjugate SGN-B7H4V"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/felmetatug-vedotin/"
}